Citadel Advisors LLC cut its holdings in shares of NuCana (NASDAQ:NCNA) by 64.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,762 shares of the company’s stock after selling 42,567 shares during the quarter. Citadel Advisors LLC owned about 0.07% of NuCana worth $240,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Sphera Funds Management LTD. purchased a new position in NuCana during the third quarter worth about $919,000. Alyeska Investment Group L.P. purchased a new position in NuCana during the third quarter worth about $2,296,000. Perceptive Advisors LLC purchased a new position in NuCana during the third quarter worth about $3,674,000. Alps Advisors Inc. purchased a new position in NuCana during the fourth quarter worth about $357,000. Finally, UBS Asset Management Americas Inc. raised its stake in NuCana by 4.5% during the fourth quarter. UBS Asset Management Americas Inc. now owns 464,600 shares of the company’s stock worth $4,697,000 after purchasing an additional 19,800 shares during the period. Hedge funds and other institutional investors own 30.70% of the company’s stock.
Separately, Zacks Investment Research downgraded shares of NuCana from a “hold” rating to a “sell” rating in a research note on Thursday, January 25th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $21.00.
Shares of NuCana stock traded up $3.80 on Friday, reaching $26.23. The company had a trading volume of 617,680 shares, compared to its average volume of 111,012. NuCana has a 52-week low of $9.32 and a 52-week high of $29.75.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/citadel-advisors-llc-trims-stake-in-nucana-plc-ncna.html.
NuCana plc, a biopharmaceutical company, engages in the development of products for the treatment of cancer. The company is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; that is in Phase Ib clinical trials for the treatment of recurrent ovarian cancer; in Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.